Challenges for inhaled drug discovery and development: Induced alveolar macrophage responses
Ben Forbes(King's College London), Alison Wolfreys(Novartis (United Kingdom)), Louise Donnelly(Lung Institute), Joel D. Parry(Age UK), Ian Robinson(AstraZeneca (Sweden)), Jan Klapwijk(GlaxoSmithKline (United Kingdom)), Kristen J. Nikula, Anthony Cahn(GlaxoSmithKline (United Kingdom)), Lea Ann Dailey(King's College London), Joseph A. Dybowski(Pfizer (United States)), Lindsay Tomlinson(Pfizer (United States)), Curtis C. Maier(GlaxoSmithKline (United Kingdom)), Philippa Pribul Allen(GlaxoSmithKline (United Kingdom)), Chris Clarke(Amgen (United States)), Raegan O’Lone(Boston University), Rhys Jones(Pfizer (United States)), Deon Hildebrand(GlaxoSmithKline (United Kingdom)), Matthew D. Reed(HRL Laboratories (United States)), David G. Hassall(GlaxoSmithKline (United Kingdom)), Joanne D. Kilgour(AstraZeneca (United Kingdom)), Mark Collinge(Pfizer (United States)), Tim McGovern
Cited by 91
Related Papers
Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trial
|The Lancet Respiratory Medicine|2021|434
Genomic Targets of Nuclear Estrogen Receptors
|Molecular Endocrinology|2004|430
Reduced Sensitivity to Charge Noise in Semiconductor Spin Qubits via Symmetric Operation
|Physical Review Letters|2016|297
Doxorubicin In Vivo Rapidly Alters Expression and Translation of Myocardial Electron Transport Chain Genes, Leads to ATP Loss and Caspase 3 Activation
|PLoS ONE|2010|127
Translational development of an ADAMTS-5 antibody for osteoarthritis disease modification
|Osteoarthritis and Cartilage|2015|118